Krystal Biotech (KRYS) Assets Average (2017 - 2026)

Krystal Biotech has disclosed Assets Average across 10 years of filings, most recently posting $1.4 billion for Q1 2026.

• Assets Average for Q1 2026 came in at $1.4 billion, up 28.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 28.19% YoY), and the FY2025 annual result was $1.2 billion, up 27.5% from the prior year.
• Assets Average came in at $1.4 billion for Q1 2026 at Krystal Biotech, up from $1.3 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.4 billion in Q1 2026 to a low of $545.1 million in Q1 2023.
• The 5-year median for Assets Average is $835.8 million (2024), against an average of $869.7 million.
• Across the five-year window, Assets Average jumped 64.91% in 2022 and declined 12.3% in 2023, its largest moves.
• Krystal Biotech's Assets Average stood at $567.4 million in 2022, then soared by 41.76% to $804.4 million in 2023, then gained by 26.7% to $1.0 billion in 2024, then increased by 26.29% to $1.3 billion in 2025, then grew by 6.09% to $1.4 billion in 2026.
• The last three Assets Average figures came in at $1.4 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.